scholarly journals A Novel Molecular Grading Model: Combination of Ki67 and VEGF in Predicting Tumor Recurrence and Progression in Non-invasive Urothelial Bladder Cancer

2012 ◽  
Vol 13 (5) ◽  
pp. 2229-2234 ◽  
Author(s):  
Jun-Xing Chen ◽  
Nan Deng ◽  
Xu Chen ◽  
Ling-Wu Chen ◽  
Shao-Peng Qiu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumor Recurrence ◽  
Urothelial Bladder Cancer ◽  
Model Combination ◽  
Non Invasive ◽  
Urothelial Bladder ◽  
Grading Model

scholarly journals Non-invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?

2019 ◽  
Vol 124 (3) ◽  
pp. 361-362
Author(s):  
Rohit K. Jain ◽  
Petros Grivas ◽  
Sumanta K. Pal
Keyword(s):  
Bladder Cancer ◽  
Urothelial Bladder Cancer ◽  
Non Invasive ◽  
Urothelial Bladder

Association of Cyclooxygenase-2 Immunoreactivity with Tumor Recurrence and Disease Progression in Superficial Urothelial Bladder Cancer

2006 ◽  
Vol 92 (2) ◽  
pp. 124-129 ◽  
Author(s):  
Ivica Mokos ◽  
Jasminka Jakić-Razumović ◽  
Zvonimir Mareković ◽  
Josip Pasini
Keyword(s):  
Bladder Cancer ◽  
Disease Progression ◽  
Stromal Cells ◽  
Tumor Recurrence ◽  
Tumor Grade ◽  
Cyclooxygenase 2 ◽  
Urothelial Bladder Cancer ◽  
Progression Of Disease ◽  
Urothelial Bladder ◽  
Cox 2

Aims and Background The main characteristic of urothelial bladder cancer is a clear predisposition to recurrence and disease progression. The aim of this study was to assess the possible relationship between cyclooxygenase-2 (COX-2) immunoreactivity in superficial urothelial bladder carcinoma and tumor grade, stage, number of recurrences and clinical disease progression. Methods In this prospective study 70 consecutive patients who underwent transurethral resection for superficial urothelial bladder cancer were included. Tumor slides were immuno-histochemically stained for COX-2, and COX-2 immunoreactivity in tumor and inflammatory stromal cells was categorized as negative or mildly, moderately or strongly positive. Patients were followed up for 2 years, and during this period the possible association of COX-2 immunoreactivity with tumor stage and grade, number of recurrences and progression of disease was evaluated. Results COX-2 immunoreactivity in tumor cells was found in 57 (81.4%) patients and did not correlate with tumor grade, stage of disease, number of recurrences, and progression of disease. COX-2 immunoreactivity in inflammatory cells was found in 16 of the 57 patients with COX-2 positive tumors, and was significantly related to the number of recurrences, time to appearance of the first recurrence, and disease progression. Conclusions COX-2 immunoreactivity in inflammatory stromal cells adjacent to the COX-2-positive tumor might be useful in clinical practice for selection of patients with a high risk of tumor recurrence and disease progression.

scholarly journals Genomic profile of urine has high diagnostic sensitivity compared to cytology in non‐invasive urothelial bladder cancer

2019 ◽  
Vol 110 (10) ◽  
pp. 3235-3243 ◽  
Author(s):  
Yosuke Hirotsu ◽  
Hitoshi Yokoyama ◽  
Kenji Amemiya ◽  
Takashi Hagimoto ◽  
Hironori Daimon ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Diagnostic Sensitivity ◽  
Genomic Profile ◽  
Urothelial Bladder Cancer ◽  
Non Invasive ◽  
Urothelial Bladder

scholarly journals Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy

2020 ◽  
Vol 43 (5) ◽  
pp. 807-819 ◽  
Author(s):  
Tician Schnitzler ◽  
Nadina Ortiz-Brüchle ◽  
Ursula Schneider ◽  
Isabella Lurje ◽  
Karolina Guricova ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Trials ◽  
Targeted Therapy ◽  
Targeted Therapies ◽  
Molecular Subtype ◽  
Genomic Alteration ◽  
High Grade ◽  
Urothelial Bladder Cancer ◽  
Non Invasive ◽  
Urothelial Bladder

Abstract Purpose Non-invasive high-grade (HG) bladder cancer is a heterogeneous disease that is characterized insufficiently. First-line Bacillus Calmette-Guérin instillation fails in a substantial amount of cases and alternative bladder-preserving treatments are limited, underlining the need to promote a further molecular understanding of non-invasive HG lesions. Here, we characterized pure HG papillary urothelial bladder cancer (pure pTa HG), a potential subgroup of non-invasive HG bladder carcinomas, with regard to molecular subtype affiliation and potential for targeted therapy. Methods An immunohistochemistry panel comprising luminal (KRT20, ERBB2, ESR2, GATA3) and basal (KRT5/6, KRT14) markers as well as p53 and FGFR3 was used to analyze molecular subtype affiliations of 78 pure pTa HG/papillary pT1(a) HG samples. In 66 of these, ERBB2 fluorescence in situ hybridization was performed. Additionally, targeted sequencing (31 genes) of 19 pTa HG cases was conducted, focusing on known therapeutic targets or those described to predict response to targeted therapies noted in registered clinical trials or that are already approved. Results We found that pure pTa HG/papillary pT1(a) HG lesions were characterized by a luminal-like phenotype associated with frequent (58% of samples) moderate to high ERBB2 protein expression, rare FGFR3 alterations on genomic and protein levels, and a high frequency (89% of samples) of chromatin-modifying gene alterations. Of note, 95% of pTa HG/papillary pT1 HG cases harbored at least one potential druggable genomic alteration. Conclusions Our data should help guiding the selection of targeted therapies for investigation in future clinical trials and, additionally, may provide a basis for prospective mechanistic studies of pTa HG pathogenesis.

Do repeated transurethral procedures under general anesthesia influence mortality in patients with non-invasive urothelial bladder cancer? A Danish national cohort study

2020 ◽  
Vol 54 (4) ◽  
pp. 281-289
Author(s):  
Marie Schmidt Erikson ◽  
Astrid Christine Petersen ◽  
Klaus Kaae Andersen ◽  
Frederik Krogsdal Jacobsen ◽  
Karin Mogensen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cohort Study ◽  
General Anesthesia ◽  
Urothelial Bladder Cancer ◽  
Non Invasive ◽  
National Cohort ◽  
Urothelial Bladder

scholarly journals Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer

2019 ◽  
Vol 20 (5) ◽  
pp. 1102 ◽  
Author(s):  
Nada Humayun-Zakaria ◽  
Roland Arnold ◽  
Anshita Goel ◽  
Douglas Ward ◽  
Stuart Savill ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Basic Knowledge ◽  
Urothelial Bladder Cancer ◽  
Cellular Processes ◽  
Non Invasive ◽  
Potential Biomarker ◽  
Urothelial Bladder ◽  
Splice Forms ◽  
Treatment And Diagnosis ◽  
Made In

Despite the incidence and prevalence of urothelial bladder cancer (UBC), few advances in treatment and diagnosis have been made in recent years. In this review, we discuss potential biomarker candidates: the tropomyosin family of genes, encoded by four loci in the human genome. The expression of these genes is tissue-specific. Tropomyosins are responsible for diverse cellular roles, most notably based upon their interplay with actin to maintain cellular processes, integrity and structure. Tropomyosins exhibit a large variety of splice forms, and altered isoform expression levels have been associated with cancer, including UBC. Notably, tropomyosin isoforms are detectable in urine, offering the potential for non-invasive diagnosis and risk-stratification. This review collates the basic knowledge on tropomyosin and its isoforms, and discusses their relationships with cancer-related phenomena, most specifically in UBC.

scholarly journals Proteomics analysis in urinary bladder cancer patients identifies urinary SOD2 as a predictive marker of recurrence

2021 ◽  
Author(s):  
Nitu Kumari ◽  
Subasa Chandra Biswal ◽  
Shweta Chaudhary ◽  
Deepankar Malalkar ◽  
Uma S Dubey ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Western Blot ◽  
Cancer Patients ◽  
Predictive Marker ◽  
Urinary Bladder Cancer ◽  
P Value ◽  
Urothelial Bladder Cancer ◽  
Non Invasive ◽  
Specificity And Sensitivity ◽  
Urothelial Bladder

Early non-invasive detection of tumor is an urgent clinical need for managing urothelial bladder cancer. Cystoscopy and cytology are the current standards for diagnosis of recurrence, but are limited by low sensitivity. Quantitative proteomics tool was employed to identify important deregulated molecules in bladder cancer tissues and validated using Western blot and immunohistochemistry analysis. A set of 1137 proteins were identified in four paired bladder cancer patients. Among these, 64 proteins were deregulated in all cases among which 9 were commonly up-regulated. The Ingenuity Pathway Analysis (IPA) generated top 11 Networks in which three commonly upregulated (SERPING1, SOD2 and HSPB6) proteins were involved and selected for further validation. Tissue expression of SOD2, SERPING1 and HSPB6 monitored in an independent sample set (n=18) by immuno-histochemical analysis showed similar profile. Western blot analysis of these proteins in urine of bladder cancer (n=26) and healthy subjects (n=10) showed a specificity and sensitivity of >80% for SOD2 and selected for further validation in a separate set (n=150) by ELISA. Significant elevation in urinary SOD2 level was found in urothelial bladder cancer patients compared to healthy controls and in recurrent cases compared to primary (p-value<0.001). Kaplan Meier survival analysis showed urinary SOD2 concentration >2,100 pg/ml was significantly associated with poorer survival and cumulative survival of patient with low SOD2 concentration was 34.4% compared to 18.9% in patient with high SOD2 at 24 months (p=0.025). The study identifies SOD2 as a non-invasive biomarker which may help to extend the period between cystoscopies during follow-up.

Sign in / Sign up

Export Citation Format

Share Document